7 news items
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
CGTX
7 May 24
degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
. and several countries in Europe including The Netherlands. Dr. Vijverberg, the primary investigator at UMC Amsterdam, explained his experience with CT1812
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
CGTX
2 Apr 24
of the central nervous system and retina. We are currently investigating our lead candidate CT1812
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX
26 Mar 24
are currently investigating our lead candidate CT1812
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
CGTX
15 Mar 24
, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our
no4lkle lc
CGTX
11 Mar 24
system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies (DLB
fuae2lpf56r4c5wglpty1xehb6g9dmc3vrtcrlmx5fjgq
CGTX
6 Mar 24
-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812
- Prev
- 1
- Next